Literature DB >> 411635

Harringtonine in acute leukemias. Clinical analysis of 31 cases.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 411635

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN： 0366-6999            Impact factor:   2.628


× No keyword cloud information.
  14 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Homoharringtonine: a phase I evaluation.

Authors:  J A Stewart; I H Krakoff
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

3.  Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells.

Authors:  T L Jiang; R H Liu; S E Salmon
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells.

Authors:  Y Takemura; T Ohnuma; T C Chou; T Okano; J F Holland
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1.

Authors:  T Okano; T Ohnuma; J F Holland; H P Koeffler; H Jui
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

6.  Homoharringtonine binds to and increases myosin-9 in myeloid leukaemia.

Authors:  Ting Zhang; Shuijie Shen; Zhijuan Zhu; Shasha Lu; Xiufeng Yin; Jiang Zheng; Jie Jin
Journal:  Br J Pharmacol       Date:  2015-12-01       Impact factor: 8.739

7.  Responses of human bone marrow progenitor cells to fluoro-ara-AMP, homoharringtonine, and elliptinium.

Authors:  G E Umbach; V Hug; G Spitzer; H Thames; B Drewinko
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 8.  Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.

Authors:  Fabio P S Santos; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2009-12

9.  An In silico Based Comparison of Drug Interactions in Wild and Mutant Human β-tubulin through Docking Studies.

Authors:  Selvaakumar Chellasamy; Sudheer M M Mohammed
Journal:  Avicenna J Med Biotechnol       Date:  2014-04

10.  MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1.

Authors:  MinRan Zhou; JiPing Zeng; XiaoMing Wang; Qing Guo; Tao Huang; HaiYu Shen; Yue Fu; LiXiang Wang; JiHui Jia; ChunYan Chen
Journal:  J Transl Med       Date:  2013-10-23       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.